U.S. Stock Market Midday Update

Moderna fell 19.34%, with increased trading volume. Based on recent key news:

1. On August 20, Moderna's personalized mRNA cancer vaccine, developed in collaboration with Merck, achieved positive results in Phase III clinical trials, significantly reducing the risk of melanoma recurrence. Despite this scientific breakthrough, concerns about valuation bubbles led to a decline in stock price. Source: CaiLianShe

2. On August 20, short sellers of Moderna faced significant losses, with the short balance as a percentage of outstanding shares dropping from 20% to 14%. As some shorts covered their positions, stock price volatility increased. Source: S3 Partners

3. On August 20, Moderna issued full-year revenue guidance below analyst expectations, with declining COVID-19 revenue continuing to impact the company's performance, putting pressure on the stock price. Source: Barron's The biotechnology industry is experiencing increased volatility; investors should exercise caution.

Stocks with High Trading Volume in the Industry

AbbVie fell 0.73%, with increased trading volume. Based on recent key news:

1. On August 18, Hisun Pharmaceutical announced a collaboration agreement with AbbVie, granting it global development rights for HSK51155, with a potential total deal value exceeding $700 million. This news positively impacted AbbVie's market outlook but did not immediately reflect in the stock price. Source: Zhitong Finance

2. On August 19, AbbVie executives exercised stock options and sold a large number of shares, potentially raising market concerns about internal confidence in the company, leading to pressure on the stock price. Source: Public Technologies

3. On August 20, analysts expressed concerns about AbbVie's market share in core immunology assets due to new competitors entering the market, which could affect long-term pricing power and growth. Source: Public Technologies The pharmaceutical industry is facing intensified competition, and innovative drug companies are facing challenges.

Amgen fell 1.74%, with increased trading volume. Based on recent key news:

1. On August 18, Amgen announced the termination of its research collaboration and licensing agreement with TScan Therapeutics. This move could impact the company's future R&D progress, leading to a decline in stock price. Source: Reuters

2. On August 17, Barclays raised Amgen's target price from $360 to $380, maintaining a neutral rating. Despite the target price increase, the neutral rating failed to boost market confidence. Source: Gelonghui

3. On August 17, the injection of tezepelumab, developed in collaboration with AstraZeneca, was officially launched in China. Although this news has a positive long-term impact, it did not significantly boost the stock price in the short term. Source: Zhitong Finance The pharmaceutical industry is facing intensified competition, and R&D risks are increasing.

Hyperliquid Strategies rose 5.00%. Based on recent news,

1. On August 17, the Druckenmiller family office disclosed a new position of $23 million in Hyperliquid Strategies shares, indicating institutional investor confidence in the company, driving the stock price up

2. On August 20, U.S. President Trump stated that the SEC Chairman is pushing for Hyperliquid to enter the U.S. market, which could become an important case for the compliance of decentralized derivatives trading platforms, further raising market expectations.

3. On August 17, the open interest in Hyperliquid's HIP-3 market reached a record high of $4.3 billion, indicating strong market demand for its products and driving up stock prices. There are noticeable inflows of funds due to changes in cryptocurrency market policies.

Stocks ranked among the top in industry market capitalization

Gilead Sciences fell 1.56%. Based on recent key news:

1. On August 17, Gilead Sciences' Chief Communications and Corporate Affairs Officer Johanna Mercier exercised stock options to purchase 25,000 shares and sold 28,000 shares on the same day at a price of approximately $137.37 to $138.04 per share. This insider trading may have raised market concerns about insider confidence in the company, leading to a decline in stock prices.

2. On August 18, analysts at BMO Capital reiterated their buy rating on Gilead Sciences with a target price of $174. However, despite the positive rating, concerns about the company's future profitability remain, affecting stock performance.

3. On August 20, Gilead Sciences' cell therapy division reported a 12% year-over-year decline in revenue, facing challenges in tumor diversification due to intensified market competition and the suspension of the STAR-121 lung cancer trial by partner Arcus Biosciences. These factors have exacerbated market concerns about the company's profitability, further depressing stock prices. Concerns about the company's profitability persist